Pemetrexed and Gemcitabine for Chemotherapy Refractory Colorectal Cancer-Results of a Phase II and Translational Research Study by Spindler, Karen-Lise Garm et al.
Journal of Cancer Therapy, 2013, 4, 44-50 
http://dx.doi.org/10.4236/jct.2013.46A2006 Published Online July 2013 (http://www.scirp.org/journal/jct) 
Pemetrexed and Gemcitabine for Chemotherapy 
Refractory Colorectal Cancer—Results of a Phase II and 
Translational Research Study* 
Karen-Lise Garm Spindler1#, Niels Pallisgaard2, Rikke Fredslund Andersen2, John Ploen1,  
Anders Jakobsen1 
 
1Department of Oncology, Vejle Hospital, Vejle, Denmark; 2Department of Biochemistry, Vejle Hospital, Vejle, Denmark. 
Email: #Karen-Lise.Garm.Spindler@slb.regionsyddanmark.dk 
 
Received April 27th, 2013; revised May 29th, 2013; accepted June 7th, 2013 
 
Copyright © 2013 Karen-Lise Garm Spindler et al. This is an open access article distributed under the Creative Commons Attribu-
tion License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly 
cited. 
ABSTRACT 
Introduction: We investigated the safety and efficacy of pemetrexed with gemcitabine in heavily pre-treated, chemo-
therapy refractory, KRAS mutated colorectal cancer (mCRC) and the prognostic value of quantitative levels of cell free 
DNA (cfDNA) in plasma. Methods: Inclusion criteria comprised; histopathologically verified, KRAS mutant, chemo-
therapy resistant mCRC, adequate organ function and performance status. Patients received pemetrexed (initially 500 
mg/m2 q3w) + gemcitabine (1250 mg/m2 days 1 and 8) until progression or unacceptable toxicity. RECIST version 1.1, 
NCI-CTCAE version 4.0 and Kaplan-Meier statistics were used for endpoint evaluation. Cell free DNA was quantified 
from pre-treatment EDTA plasma-samples by an in-house qPCR. Results: Forty patients were included. The median 
number of cycles was 3 (range 0 - 12). Thirty-six percent obtained disease stabilisation, but no objective response was 
observed. Median PFS and OS were 2.8 (range 2.1 - 4.0) and 5.4 (range 4.3 - 7.0) months, respectively. Adverse events 
caused immediate discontinuation of treatment or delay of the next cycle and consequently discontinuation in 5 patients. 
Translational research revealed a shorter PFS and OS with increasing levels of cfDNA. The median PFS in patients with 
cfDNA levels above the 75 percentile was 2 months compared to 4 months in the remaining patients, HR 3.23 (1.05 - 
9.89), p = 0.0008. The median OS was 3 and 6 months, respectively, HR 2.9 (95%CI 0.98 - 8.34). Cox regression 
analysis confirmed that cfDNA remained a significantly independent prognostic factor for both PFS and OS. Conclu-
sion: Pemetrexed and gemcitabine did not prove sufficient benefit and unacceptable toxicity was observed. The poten-
tial value of cfDNA should be investigated further. 
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1. Introduction 
A substantial proportion of the colorectal cancer patients 
who fail on standard chemotherapy is in good perform- 
ance status and eligible for other treatment options. 
KRAS status is decisive for effect of combination 
therapy with epidermal growth factor receptor inhibitors, 
since benefit is confined to KRAS wild type patients. 
Thus, chemotherapy refractory patients with KRAS mu- 
tant disease have no established treatment options, and 
experimental trials are warranted to identify new possible 
effective regimens for this group of patients.  
Pemetrexed is a methotrexate analogue and a folate 
antimetabolite inhibiting folate dependent enzymatic 
pathways essential for cell replication. The mechanisms  
of cytotoxicity are partly thymidylate synthase (TS) inhi- 
bition, partly targeting other enzymes such as the dihy- 
drofolate reductase (DHFR) and glycinamide ribonucleo- 
tide formyl transferase (GARFT) involved in purine 
synthesis [1]. Pemetrexed has demonstrated efficacy in 
preclinical models of colorectal cancer cell lines [2] and 
response rates of 15.4 and 17.2 in first line monotherapy 
studies [3,4]. It has also been evaluated in combination 
with both irinotecan and oxaliplatin with non-inferior 
response rates and acceptable toxicity compared to stan- 
dard treatment of metastatic disease [5-7] Preliminary 
data suggest that 5FU resistant tumours might respond to  
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pemetrexed based treatment; however, this aspect has not 
been sufficiently investigated [8-10]. 
Gemcitabine has shown effect in colorectal cancer, but 
minimal efficacy as a single agent in fluoropyrimidine 
resistant disease. However, a recent data analysis of 144 
patients with refractory mCRC, who were treated with 
combinations of gemcitabine and fluoropyrimidines, re- 
vealed a RR above 30%. Toxicity was manageable, ex- 
cept from regimens including bolus 5FU [11].  
An in vitro-synergistic effect between pemetrexed and 
gemcitabine has been demonstrated in different tumour 
types, including the colorectal cancer HT29, LoVo, 
WiDr and LRWZ cell lines [12,13] Pemetrexed accumu- 
lates cells in the S-phase, which helps gemcitabine in- 
corporation and apoptosis, and pemetrexed enhances 
upregulation of cCK, which phosphorylates gemcitabine 
and renders the drug active. Hereby pemetrexed has the 
potential to sensitize cells to the cytotoxic activity of 
gemcitabine. Different dosing schedules of pemetrexed 
and gemcitabine combinations have been evaluated and 
[14] the most efficient regimen with the lowest degree of 
toxicity has been established by a direct comparison 
made by Ma et al. in NSCLC patients [15]. Consequently, 
the combination is an established treatment option in 
NSCLC and both pre-clinical and clinical data support 
the investigation in chemotherapy refractory CRC. 
Translational research is a prerequisite for improve- 
ment of patient selection for relevant therapy and for 
avoiding treatment with no benefit and harmful toxicity. 
We have previously shown that circulating free DNA 
(cfDNA) can be detected in the peripheral blood and that 
the level of cfDNA alleles was correlated to outcome of 
third line treatment in a cohort of patients with heavily 
pre-treated mCRC [16]. Prospective collection of blood 
samples for TR studies is therefore highly relevant in this 
setting. 
The present study aimed to investigate the efficacy and 
safety of the combination of pemetrexed and gemcitabine 
in heavily pre-treated, chemotherapy resistant, KRAS 
mutated colorectal cancer. In parallel, translational re- 
search studies were conducted focusing on quantitative 
measurement of cfDNA in the blood. 
2. Materials and Methods 
2.1. Patient Selection 
Patients with histologically verified colorectal cancer 
with KRAS mutations, who had failed standard chemo- 
therapy with fluoropyrimidines, oxaliplatin and irinote- 
can were eligible for the study. Other requirements in- 
cluded measurable disease according to RECIST; age ≥ 
18 years; Eastern Cooperation Oncology Group per- 
formance status of 0 - 2; adequate bone marrow and bio- 
chemical function and acceptance of sampling for trans- 
lational research. 
Patients were excluded who had clinical signs of or 
known brain metastasis; other clinically significant con- 
current illness at the discretion of the investigator; preg- 
nant or breastfeeding patients; other experimental treat- 
ment within 30 days prior to study entry; planned radia- 
tion of target lesions and concurrent vaccination against 
yellow fever. 
All patients provided signed informed consent before 
study entry and the protocol was approved by the Danish 
Medicines Agency and The Regional Scientific Ethical 
Committee of Southern Denmark. The study was con- 
ducted in accordance with the Good Clinical Practice 
guidelines as issued by the International Conference on 
Harmonization and the Declaration of Helsinki.  
2.2. Treatment 
Patients initially received intravenous pemetrexed 500 
mg/m2 q3w combined with gemcitabine 1250 mg/m2 
days 1 and 8. A dosage cap at 2 m2 was required and a 
75% dosing schedule used in patients who had previ- 
ously received chemotherapy in reduced dosing levels. 
Out of safety concerns after the first 25 patients the 
starting dose level was reduced to 80% of the primarily 
planned schedule (pemetrexed 400 mg/m2 and gemcit- 
abine 1000 mg/m2). Premedication with oral predniso- 
lone 25 mg was given twice the day before, on the treat- 
ment day and the day after all doses of pemetrexed. An- 
tiemetics according to local guidelines supplemented 
with 350 µg oral folic acid daily and 1000 µg vitamin 
B12 intramusculary q9w were required.  
CT scans of chest and abdomen were used for evalua- 
tion of response according to RECIST (version 1.1) and 
performed less than 3 weeks prior to first treatment given 
and every 9 weeks during treatment. Follow-up scans 
were performed every three months in patients who 
stopped treatment on stable disease and continued until 
first sign of progression. The NCI-CTCAE version 4.0 
was used to assess toxicity and recorded at every visit for 
treatment until resolved. During combination therapy any 
dose reduction was applied to both drugs regardless of 
the type of toxicity.  
Patients were treated until progression, unacceptable 
toxicity, prolonged treatment pause or withdrawal of 
consent. 
2.3. Trial Design and Statistics 
The trial was designed as a single arm, phase II study 
according to Simon’s two stage designs. A response rate 
higher than 25% was considered clinically relevant with 
the perspective of further investigations, whereas less 
than 10% was deemed unacceptable. α was set to 0.05 
and β to 0.1 (a power of 90%). Consequently, the initially  
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planned sample size for the first step was 31 patients. If 
≥4 patients achieved an objective response to treatment, 
enrolment would be extended by another 24 patients to a 
maximum of 55 patients. 
The primary endpoint was response according to RE- 
CIST version 1.1. Secondary endpoints included toler- 
ability graded according to NCI-CTCAE version 4.0, 
progression free survival (PFS) calculated from date of 
first treatment until date of progression or death from any 
cause, and overall survival (OS) as defined from date of 
first treatment until death from any cause. 
The association between marker status and objective 
response, baseline characteristics and toxicity rates was 
determined by two-sided t-tests or χ²-test. The Kaplan- 
Meier method was used to estimate PFS and OS. A mul- 
tivariate Cox regression analysis was performed to ex- 
amine whether the different variables were associated 
with reduced survival. P-values referred to two-tailed 
tests and were considered significant when p ≤ 0.05. Sta- 
tistics were carried out using the NCSS statistical soft- 
ware 2007 v.07.1.5 (NCSS Statistical Software, Utah 
84,037, USA, www.ncss.com). 
2.4. Biomarker Collection and Analysis 
Archived tumor tissue was obtained and blood samples 
for translational research were drawn at baseline and 
prior to each cycle. KRAS tumor status was determined 
prior to treatment. Plasma samples were analysed for 
cfDNA by an in-house qPCR method as previously pub- 
lished [16]. 
3. Results 
3.1. Patients 
During the period from April 2010 to Aug 2011, 40 pa- 
tients were included in the study comprising 19 female 
and 21 male patients. Seventy three percent of the pa- 
tients had been diagnosed with primary, disseminated 
disease and the median time from primary diagnosis until 
inclusion in the study was 23 months (range 5 - 73 
months). All patients had progressed on standard cyto- 
toxic treatment and the majority (73%) had also received 
anti-angiogenesis therapy. The pre-treatment characteris- 
tics are presented in Table 1. 
 
Table 1. Pre-treatment characteristics (N = 40) and correlation to cfDNA. 
Characteristic Number %** cfDNA alleles/ml plasma Median (95%CI) p-value 
Age median years (range) 66 (40 - 80)    
<age 66 21 48 20,160 (6977 - 52,731) p > 0.05 
>age 66 19 52 8011 (9070 - 25,917)  
Gender     
Female 19 48 29,652 (20,160 - 73,530) 0.0009 
Male 21 53 11,285 (6848 - 18,011)  
ECOG performance status     
0 19 48 15,446 (6997 - 27,794)  
1 18 45 25,028 (8611 - 43,190) p > 0.05 
2 3 8 325,692* (NA)  
Site of primary tumor     
Rectum 16 40 28,325 (9070 - 44,104) p > 0.05 
Colon 23 58 15,486 (6997 - 25,917)  
NA 1 3 NA  
Sites of metastatic disease     
Liver metastasis present 31 78 25,047 (15,486 - 41,118) p = 0.03 
No liver metastasis 9 23 7567 (4677 - 32,457)  
Lung metastasis present 30 75 21,510 (12,062 - 32,457) p > 0.05 
No lung metastasis 10 25 19,815 (6073 - 44,104)  
KRAS status in plasma     
Mutation detected 33 83 25,008 (12,400 - 32,457) p > 0.05 
No mutation detected 7 18 6977 (3849 - 47,043)  
* only 3 observations, and therefore (by t-test of PS 0 vs 3; p=0.05);**rounding of numbers. 
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Thirty-nine of the forty patients commenced treatment 
as planned and the median number of cycles was 3 (range 
0 - 12). The reasons for discontinuation were; disease 
progression in the majority of patients (26 (67%)), toxi- 
city (1 (2%)), postponed course due to adverse events (4 
(10%)) and patient’s wish (8 (21%)). After the interim 
analysis showed unsatisfactory response rates the pa- 
tients still on treatment were informed and consequently 
discontinued protocol treatment. A total of 25 patients 
received ≥3 cycles and were available for radiological 
response evaluation. An additional three patients had an 
evaluation scan after the second cycle and showed pro- 
gressive disease and were consequently included in the 
interim analysis for efficacy assessment.  
3.2. Efficacy 
A total of 10 patients (10/28 = 36%) obtained disease 
stabilisation, but no objective responses were observed, 
and 18 patients progressed before or at the first assigned 
response evaluation. The study was designed to include 
31 evaluable patients in the interim analysis and continue 
into step 2 if four or more patients responded. Since none 
of the first 28 patients showed objective response after 3 
cycles, accrual for the second step of the study was can- 
celled. At time of analysis seven patients were still alive, 
and the median PFS and OS were 2.8 (range 2.1 - 4.0) 
and 5.4 (range 4.3 - 7.0) months, respectively (Figure 1).  
3.3. Safety 
All AEs and SAEs were recorded including disease re- 
lated events. There were no treatment related deaths or 
SUSARs reported, but a total of 35 SAEs were recorded 
as possibly treatment related. The majority of the events 
were episodes of pyrexia, which, due to standard proce- 
dures, caused hospital admission to exclude febrile neu- 
tropenia. However, initially the high frequency of com- 
plications led to modification of the protocol and a pri- 
mary dose reduction. Toxicity resulted in immediate dis- 
continuation of treatment (n = 1) or postponement of the 
next planned cycle and consequently discontinuation of 
therapy for a total of five patients.  
3.4. Translational Research 
All patients had pre-treatment blood samples available 
for measurement of cfDNA in the plasma. The mean and 
median cfDNA levels were 99,200 (range 2210 - 
2,259,700) and 19,800 (95% CI 11,300 - 27,800) alleles 
per ml. The 25th percentile was 7800 and the 75th per- 
centile 42,700 alleles per ml. The level of cfDNA was 
investigated in relation to all pre-treatment characteristics 
as shown in Table 1. A significantly higher median 
cfDNA level was revealed in female patients (29,650  
 
(a) 
 
(b) 
Figure 1. Kaplan Meier survival plots of PFS and OS in the 
total cohort of 40 patients. 
 
alleles per ml) compared to male (median 11290 alleles 
per ml, and in patients with liver metastasis compared to 
those with non-liver metastatic disease (median 25,000 
and 7570, p = 0.029, respectively. There was a margin- 
ally higher cfDNA level in the three patients with poor 
PS (PS 2), compared to the remaining groups (p = 0.049), 
and non-significant differences within the remaining pa- 
rameters (data not shown). 
Kaplan-Meier survival plots for PFS and OS revealed 
a shorter PFS and OS with increasing levels of pre- 
treatment cfDNA when divided into quartiles of cfDNA 
levels. The median PFS in patients with the highest level 
of cfDNA was only 2 months compared to 4 months in 
the remaining patients, HR 3.23 (1.05 - 9.89), p = 0.0008. 
This translated into a significant difference in median 
overall survival of three and six months, respectively, 
HR 2.9 (95%CI 0.98 - 8.34), (Figure 2). The number of 
events allowed for a multivariate cox regression analysis 
including the chosen variables age, gender, PS, presence 
of liver metastases, and plasma cfDNA divided into  
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quartiles. Only cfDNA remained a significantly inde- 
pendent prognostic factor for both PFS and OS as pre- 
sented in Table 2. 
4. Discussion 
Although a substantial fraction of the patients obtained 
stabilisation of the disease, no objective response was 
observed and it must be concluded that, despite a pre- 
clinical as well as clinical rationale for combining pe- 
metrexed and gemcitabine, we failed to demonstrate a 
clinically meaningful efficacy of this combination.  
The search for effective treatment options for heavily 
pre-treated patients with chemotherapy refractory disease 
has taken considerable focus, but results have been dis- 
appointing. KRAS mutant, chemotherapy resistant disease 
 
   
(a)                                                            (b) 
Figure 2. Kaplan Meier plots of the total cohort of patients dichotomised at the 75 percentile, which show increasing PFS and 
OS with decreasing pre-treatment plasma cfDNA levels. The dotted line represents patients with cfDNA levels above the 75 
percentile and the full line the remaining patients. 
 
Table 2. Multivariate cox regression analysis of PFS and OS. 
PFS OS 
Variables 
Risk Ratio (95% CI) p-value Risk Ratio (95% CI) p-value 
Plasma cfDNA quartiles**     
  1.81 1.7 
  (1.1 - 3.0) 
0.02 
(1.1 - 2.6) 
0.02 
PS*,**     
  0.81 1.02 
  (0.45 - 1.46) 
0.48 
(0.6 - 1.8) 
0.93 
Age     
 <median† 0.64 0.84 
 >median (0.3 - 1.4) 
0.25 
(0.42 - 1.7) 
0.61 
Gender     
 Female† 1.19 1.5 
 Male (0.42 - 3.3) 
0.74 
(0.6 - 3.6) 
0.34 
Liver metastasis      
 Yes 0.61 1.0  
 No (0.22 - 1.7) 
0.34 
(0.4 - 2.5) 0.95 
†reference group; *PS = Performance Status (ECOG); **entered as a continuous variable; The Risk Ratio refers to moving from the reference group to the other 
roup or changing one step in parameters entered as continuous variables. g 
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therefore remains a major challenge to the treating phy- 
sician and holds a poor prognosis. The median OS of our 
patients in this study was only 5.4 months, ranging from 
4.3 - 7.0 months, and the PFS 2.8 months (2.1 - 4.0). In 
comparison, a retrospective study investigating mitomy- 
cin C in 109 refractory mCRC patients showed OS of 4.5 
months [17] and Vorinostat combined with 5-FU/LV was 
used in another study and produced a median PFS and 
OS of 2.4 and 6.5 months, respectively. Only one out of 
43 patients achieved a partial response [18]. A Japanese 
study investigated salvage S-1 monotherapy in 23 pa- 
tients who had failed on 5-FU, oxaliplatin and irinotecan 
and observed SD in 17% of the patients but no objective 
responses. The median PFS was 2.7 months (range 0.4 - 
12.6) and OS 4.7 months (1.0 - 28.9) [19]. Thus, our data 
are comparable to the literature and unfortunately illus- 
trate the rapidly progressive nature of disease at this 
stage. Results of new targeted agents are eagerly awaited, 
since traditional chemotherapeutic drugs have failed in 
this setting. 
The present study has also underlined that although 
these patients are seemingly in good performance status 
with apparently healthy bone marrow function, a general 
exhaustion of the organ function renders these patients 
more at risk of toxicity. Results are definitely not com- 
parable to chemotherapy naïve patients, who according 
to the literature showed significantly less toxicity from 
the present treatment regimen and we chose to reduce the 
starting dose. It is reasonable to conclude that despite a 
chance of disease stabilisation, the price paid in terms of 
hospital visits, admissions and need for surveillance is 
too high to justify active treatment of this group of pa- 
tients. On the other hand, it must not be dismissed that 
upon careful selection a small subgroup could benefit 
from aggressive treatment in this setting. Therefore, reli- 
able selection criteria should be investigated. 
The present trial has enabled us to confirm the level of 
cfDNA alleles in the plasma to reflect disease behavior. 
As also demonstrated in two previous phase II studies by 
our group [16 and data in press], a high level of cfDNA 
was associated with a poor prognosis, and stabilisation of 
disease seemed confined to patients with low plasma 
levels. Consequently, it is likely that the level of cfDNA 
in the peripheral blood can serve as a selection criterion 
and that we hereby can avoid unnecessary toxicity and 
improve the clinical results. Prospective studies investi- 
gating this issue should therefore be designed.  
In conclusion, pemetrexed and gemcitabine did not 
provide sufficient benefit in this setting and unacceptable 
toxicity was observed. However, despite the small sam- 
ple size translational research has confirmed the clinical 
potential of measuring cfDNA levels prior to treatment 
and further studies on these aspects are highly relevant. 
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